Haleon HLN
NYSE HLN
$9.85 -0.02 (-0.20%)
At close: Aug 20, 2026 · 10:53 AM UTC

Haleon (HLN) Liabilities and Shareholders Equity (2021 - 2026)

Haleon's (HLN) quarterly Liabilities and Shareholders Equity came in at $43.7 billion in Q2 2026, little changed on a QoQ basis from $43.7 billion in Q4 2025.

Haleon (HLN) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends

Haleon (HLN) has 6 years of Liabilities and Shareholders Equity data on file, last reported at $43.7 billion in Q2 2026.

  • Quarterly Liabilities and Shareholders Equity changed N/A year-over-year to $43.7 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $173.6 billion (changed N/A YoY) and the FY2025 annual result came in at $43.4 billion, down 1.05% from the prior year.
  • Liabilities and Shareholders Equity was little changed at $43.7 billion in Q2 2026, from $43.7 billion in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $56.7 billion in Q2 2022 to a low of $40.8 billion in Q4 2022.
  • A 5-year average of $44.5 billion and a median of $43.2 billion in 2023 frame the typical range for Liabilities and Shareholders Equity.
  • Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity fell 24.57% — and 2024, when it climbed 4.2%.
  • Tracing HLN's Liabilities and Shareholders Equity over 5 years: stood at $40.8 billion in 2022, then climbed by 3.51% to $42.3 billion in 2023, then gained by 4.2% to $44.0 billion in 2024, then declined by 0.74% to $43.7 billion in 2025, then declined by 0.01% to $43.7 billion in 2026.
  • The last three Liabilities and Shareholders Equity figures came in at $43.7 billion (Q2 2026), $43.7 billion (Q4 2025), and $44.0 billion (Q4 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Haleon 43.76 Bn 42.79 Bn - 43.71 Bn
2 Teva Pharmaceutical Industries 43.38 Bn 39.73 Bn 2.15 Bn 39.86 Bn
3 Zoetis 31.61 Bn 29.93 Bn 1.05 Bn 15.08 Bn
4 Takeda Pharmaceutical 28.64 Bn 22.84 Bn 5.10 Bn 98.27 Bn
5 United Therapeutics 22.20 Bn 19.54 Bn 683.80 Mn 7.22 Bn
6 Viatris 18.82 Bn 17.93 Bn 1.46 Bn 35.04 Bn
7 Neurocrine Biosciences 15.67 Bn 15.28 Bn 935.80 Mn 5.36 Bn
8 Elanco Animal Health 12.11 Bn 11.58 Bn 798.00 Mn 13.56 Bn
9 Dr Reddys Laboratories 10.10 Bn 9.94 Bn - 6.18 Bn
10 Alkermes 8.21 Bn 7.55 Bn 397.90 Mn 4.39 Bn

Historic Data

Download Data
DateValue
Jun 30, 2026 43.71 Bn
Dec 31, 2025 43.72 Bn
Dec 31, 2024 44.04 Bn
Jun 30, 2024 42.15 Bn
Dec 31, 2023 42.27 Bn
Jun 30, 2023 42.75 Bn
Dec 31, 2022 40.84 Bn
Jun 30, 2022 56.68 Bn
Dec 31, 2021 46.44 Bn